BiotechTube

Oral Upadacitinib + Intravenous Methylprednisolone + Oral Upadacitinib Placebo + Oral prednisolone Taper + Oral Prednisone - Hospital Dose Steroids

ApprovedRecruiting
0 views this week 0 watching⚡ Active
Interest: 50/100
50
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Ulcerative Colitis Acute

Conditions

Ulcerative Colitis Acute

Trial Timeline

Jan 16, 2026 → Dec 1, 2030

NCT ID
NCT07258771

About Oral Upadacitinib + Intravenous Methylprednisolone + Oral Upadacitinib Placebo + Oral prednisolone Taper + Oral Prednisone - Hospital Dose Steroids

Oral Upadacitinib + Intravenous Methylprednisolone + Oral Upadacitinib Placebo + Oral prednisolone Taper + Oral Prednisone - Hospital Dose Steroids is a approved stage product being developed by AbbVie for Ulcerative Colitis Acute. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07258771. Target conditions include Ulcerative Colitis Acute.

What happened to similar drugs?

14 of 20 similar drugs in Ulcerative Colitis Acute were approved

Approved (14) Terminated (5) Active (6)
✅Azathioprine + PlaceboCelltrionApproved
✅Filgotinib MaleateEisaiApproved
✅AdalimumabAbbVieApproved
✅Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg + Golimumab treatment optimization.MerckApproved
✅GolimumabMerckApproved
✅GolimumabMerckApproved
✅Prefilled Syringe delivery of Golimumab + Smartject Device delivery of GolimumabMerckApproved

Hype Score Breakdown

Clinical
20
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07258771ApprovedRecruiting

Competing Products

20 competing products in Ulcerative Colitis Acute

See all competitors
ProductCompanyStageHype Score
Mirikizumab SC + Mirikizumab IV + Placebo SCEli LillyPhase 3
40
MirikizumabEli LillyPhase 2
35
Azathioprine + PlaceboCelltrionApproved
35
CT-P13 SC (Infliximab)CelltrionPhase 3
40
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
44
TacrolimusAstellas PharmaPhase 3
40
tacrolimus + PlaceboAstellas PharmaPhase 3
40
Filgotinib MaleateEisaiApproved
50
AJM300 + PlaceboEisaiPhase 3
40
GSK3050002 + PlaceboEisaiPhase 1
29
adalimumab + placeboEisaiPhase 3
40
E6007 + PlaceboEisaiPhase 2
35
KHK4083 + PlaceboKyowa KirinPhase 2
35
KHK4083 + PlaceboKyowa KirinPhase 1
29
Arm1 + Arm 2Zydus LifesciencesPhase 2
35
Mirikizumab + MirikizumabEli LillyPhase 3
44
Mirikizumab IV + Mirikizumab SC + Vedolizumab IV + Placebo IV + Placebo SCEli LillyPhase 3
32
LY3471851 + PlaceboEli LillyPhase 2
27
Mirikizumab + PlaceboEli LillyPhase 2
35
LY4268989 + PlaceboEli LillyPhase 2
42